Skip to main content

Advertisement

Table 1 Baseline characteristics of patients in the trials included in the meta-analysis

From: Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries

Study Country Study design Treatment regimen No. of patients Pregnancy time when tenofovir was started (w) Age (mean ± SD, y) HBV DNA (log10 IU/ml) NOS score
Greenup AJ [20] Austria Cohort Tenofovir 300 mg daily 58 30–32 30 ± 8.5 7.94 ± 0.78 7
   Lamivudine 100 mg daily 52   28 ± 5.3 7.72 ± 0.61  
   No medication 20   28 ± 5 8 ± 0.04  
Chen HL [36] China Cohort Tenofovir 300 mg daily 62 32 32.41 ± 3.12 8.25 ± 0.45 9
   No medication 56   32.45 ± 3.2 8.24 ± 0.35  
Pan CQ [37] China RCT Tenofovir 300 mg daily 97 30–32 27.4 ± 3.0 8.2 ± 0.5 NA
   Usual care 100   26.8 ± 3.0 8.0 ± 0.7  
Celen MK [38] Turkey Cohort Tenofovir 300 mg daily 21 18–27 28.2 ± 4.1 8.28 6
   Untreated 24   26.9 ± 2.9 8.31  
Kochaksaraei GS [39] Canada Cohort Tenofovir 300 mg daily 23 28 (21–32) 30(28–34) 7.7(3.2–8.1) 6
   Untreated 138   32(29–36) 2.3(1.6–3.1)  
Chen WJ [40] China Cohort Tenofovir 300 mg daily 30 23.9 ± 1.9 28.67 ± 5.71 ≥6.0 7
   Telbivudine 600 mg daily 79   31.13 ± 6.27 ≥6.0  
   Untreated 44   29.86 ± 5.05 ≥6.0  
Wan JY [41] China Cohort Tenofovir 300 mg daily 74 28 28.5 ± 4.2 7.69 ± 0.54 8
   Untreated 42   27.9 ± 4.0 7.57 ± 0.48  
Qi LW [42] China Cohort Tenofovir 300 mg daily 54 6 27.5 ± 3.6 7.01 ± 0.98 7
   Untreated 32   26.4 ± 3.1 6.51 ± 1.03  
Deng J [43] China Cohort Tenofovir 300 mg daily 20 10 26.15 ± 2.56 NR 7
   Untreated 20   28.32 ± 2.45 NR  
  1. Abbreviation: SD standard deviation, NR not reported, NA not available, NOS Newcastle-Ottawa scale